Insider Buying: Immunic, Inc. (NASDAQ:IMUX) CEO Purchases 15,000 Shares of Stock

Immunic, Inc. (NASDAQ:IMUX) CEO Daniel Vitt purchased 15,000 shares of the firm’s stock in a transaction dated Wednesday, June 4th. The stock was acquired at an average price of $0.77 per share, with a total value of $11,550.00. Following the purchase, the chief executive officer now directly owns 29,000 shares of the company’s stock, valued at approximately $22,330. The trade was a 107.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Immunic Stock Performance

Immunic stock opened at $0.79 on Friday. The stock has a market cap of $75.54 million, a PE ratio of -0.64 and a beta of 1.73. Immunic, Inc. has a one year low of $0.56 and a one year high of $2.11. The stock has a fifty day moving average of $0.96 and a 200 day moving average of $1.05.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.25) EPS for the quarter, meeting analysts’ consensus estimates of ($0.25). As a group, sell-side analysts predict that Immunic, Inc. will post -0.94 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on IMUX shares. Wall Street Zen cut Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Immunic in a research note on Thursday, May 1st. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Immunic in a research note on Thursday. William Blair restated an “outperform” rating on shares of Immunic in a research note on Friday, May 16th. Finally, B. Riley reiterated a “buy” rating and set a $5.00 price objective (down previously from $6.00) on shares of Immunic in a research report on Friday, May 23rd. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Immunic has an average rating of “Buy” and an average price target of $11.60.

Institutional Trading of Immunic

A number of hedge funds have recently bought and sold shares of IMUX. Invesco Ltd. purchased a new stake in Immunic during the fourth quarter valued at $37,000. Renaissance Technologies LLC increased its position in Immunic by 45.6% in the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after buying an additional 177,542 shares in the last quarter. Barclays PLC purchased a new stake in Immunic in the fourth quarter worth about $84,000. 683 Capital Management LLC increased its position in Immunic by 2.2% in the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after buying an additional 15,349 shares in the last quarter. Finally, Bridgeway Capital Management LLC increased its position in Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after buying an additional 22,200 shares in the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.